Articles tagged with: EHA 2009 Meeting
News»

A recent Phase 2 study, presented at the European Hematology Association (EHA) meeting, showed that a regimen of Velcade (bortezomib), dexamethasone (Decadron), and doxorubicin (Adriamycin), or VDD, resulted in improved kidney impairment in multiple myeloma patients.
Multiple myeloma patients often face kidney complications including acute light chain induced renal failure (ARF). ARF is a serious complication that can lead to permanent kidney dysfunction and reliance on continual hemodialysis. A normal kidney produces urine for excretion but reabsorbs proteins so they do not leave the body. Anti-myeloma therapy that prevents …